Reig et al. suggested that DAA treatment may promote HCC-R, whereas Waziry et al. found no significant differences between DAA and IFN treatments in a meta-analysis adjusted for age and observation period [20,33]. The gene discussed is IFNA1; the disease is hepatocellular carcinoma.